All In Biotech

Drug Trial Radar · NCT04542447

To Evaluate Safety and Efficacy of Nuvastatic as an Immunomodulator Adjuvant Therapy in COVID-19 Patients.

An Open Label Proof of Concept Study to Assess Aspects of Safety and Efficacy of Nuvastatic™ (C5OSEW5050ESA) as an Immunomodulator Adjuvant Therapy to the Standard Care of Treatment in Covid 19 Patients.

Last checked: Nov 19, 2026Latest source record: Sep 10, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

10

Planned (sponsor's estimate)

Start

Sep 1, 2020

Primary completion

Sep 30, 2020

Study completion Sep 30, 2020

Sponsor

Lead sponsor
Natureceuticals Sdn BhdIndustry
Sponsor type
Industry
First posted
Sep 9, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A two arm open label multi-centered randomized interventional trial is proposed to assess aspects of safety and efficacy of Nuvastatic™ (Serial No: C5OSEW5050ESA) . Two parallel groups of (1:1) ratio comparing Nuvastatic™ versus standard care will be conducted on patients on oxygen saturation (SaO2) of 94% or less while they are breathing ambient air or a ratio of the partial pressure of oxygen (Pao2) to the fraction of inspired oxygen (Fio2) (PaO2:FiO2) at or below 300 mg Hg. Primary Outcome Measures: time to clinical improvement, defined as the time from randomization to an improvement of two points (from the status at randomization) on a seven-category ordinal scale or live discharge from the hospital, whichever comes first. Secondary Outcome Measures: Clinical status as assessed with the seven-category ordinal scale on days 7 and 14, mortality at day 28. 1. The duration of mechanical ventilation. 2. The duration of hospitalization in survivors. 3. The time (in days) from treatment initiation to death. 4. Virologic measures included the proportions with viral RNA detection over time and viral RNA titer area under-curve (auc) measurements.

Conditions

  • Covid19

Interventions

  • NuvastaticDrug

    Polymolecular botanical standardized extract Orthosiphon stamineus/Orthosiphon aristatas as an immunomodulator adjuvant therapy

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To evaluate safety and efficacy Nuvastatic™ (C5OSEW5050ESA)Time frame: 14 Days
  2. IL-6 reductionTime frame: 14 Days
  3. Serum c-reactive protein (CRP)Time frame: 14 Days
  4. IgGTime frame: 14 Days
  5. HbTime frame: 14 Days
  6. Total leucocyte countTime frame: 14 Days
  7. F2-IsoprostaneTime frame: 14 Days
  8. Improvement in ARDS associated clinical symptoms causeTime frame: 14 Days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Navin Hospital

    Ghaziabad, Uttar Pradesh, India · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.